Highlight
– Clesrovimab is a long-acting monoclonal antibody targeting the RSV fusion protein to prevent RSV disease.
– In a phase 3 randomized trial, a single 105-mg intramuscular dose significantly reduced RSV-associated medically attended lower respiratory infection by 60.4%.
– RSV-associated hospitalizations decreased by 84.2% with clesrovimab compared to placebo.
– Safety profile of clesrovimab was comparable to placebo, with no increase in serious adverse events.
